M. Kathryn  Fink net worth and biography

M. Fink Biography and Net Worth

VP of Stryker
M. Kathryn Fink serves as Chief Human Resource Officer, Vice President of the Company. She is responsible for all human resources policies, practices, planning, direction and activities, including Talent Acquisition, Talent Development, Total Rewards and HR Shared Services. Ms. Fink began her career with us in 2013 as Vice President, Talent Management and became Vice President, Human Resources, MedSurg and Neurotechnology Group in 2015. Prior to joining us, she held a number of HR roles of increasing scope and complexity at Cintas Corporation and Ethicon Endo-Surgery, a division of Johnson & Johnson. Ms. Fink holds a Bachelor of Science degree from Kenyon College and Master's degree in human resource management (HRM) from Rutgers' School of Management and Labor Relations.

What is M. Kathryn Fink's net worth?

The estimated net worth of M. Kathryn Fink is at least $3.86 million as of September 17th, 2024. Fink owns 10,042 shares of Stryker stock worth more than $3,864,965 as of November 23rd. This net worth estimate does not reflect any other assets that Fink may own. Learn More about M. Kathryn Fink's net worth.

How do I contact M. Kathryn Fink?

The corporate mailing address for Fink and other Stryker executives is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. Stryker can also be reached via phone at (269) 385-2600 and via email at [email protected]. Learn More on M. Kathryn Fink's contact information.

Has M. Kathryn Fink been buying or selling shares of Stryker?

M. Kathryn Fink has not been actively trading shares of Stryker during the past quarter. Most recently, M Kathryn Fink sold 7,347 shares of the business's stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a transaction totalling $2,696,202.06. Following the completion of the sale, the vice president now directly owns 10,042 shares of the company's stock, valued at $3,685,213.16. Learn More on M. Kathryn Fink's trading history.

Who are Stryker's active insiders?

Stryker's insider roster includes Yin Becker (VP), William Berry, Jr. (VP), Glenn Boehnlein (CFO), Srikant Datar (Director), Roch Doliveux (Director), M. Fink (VP), Robert Fletcher (VP), Allan Golston (Director), Kevin Lobo (Chair and CEO), Katherine Owen (VP), James Pierce (Insider), Bijoy Sagar (VP), Timothy Scannell (COO), and Ronda Stryker (Director). Learn More on Stryker's active insiders.

Are insiders buying or selling shares of Stryker?

In the last year, insiders at the medical technology company sold shares 10 times. They sold a total of 490,063 shares worth more than $165,955,919.20. The most recent insider tranaction occured on November, 7th when CEO Kevin Lobo sold 57,313 shares worth more than $21,131,303.10. Insiders at Stryker own 5.9% of the company. Learn More about insider trades at Stryker.

Information on this page was last updated on 11/7/2024.

M. Kathryn Fink Insider Trading History at Stryker

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/17/2024Sell7,347$366.98$2,696,202.0610,042View SEC Filing Icon  
9/13/2024Sell2,121$370.00$784,770.0010,042View SEC Filing Icon  
1/11/2023Sell6,571$257.69$1,693,280.999,264View SEC Filing Icon  
1/9/2023Sell3,536$260.00$919,360.009,264View SEC Filing Icon  
11/2/2022Sell340$219.68$74,691.2012,774View SEC Filing Icon  
4/8/2021Sell4,000$250.00$1,000,000.00View SEC Filing Icon  
9/19/2019Sell28,690$220.97$6,339,629.30View SEC Filing Icon  
2/4/2019Sell180$176.77$31,818.60View SEC Filing Icon  
11/5/2018Sell415$166.56$69,122.40View SEC Filing Icon  
11/30/2017Sell150$154.46$23,169.00View SEC Filing Icon  
See Full Table

M. Kathryn Fink Buying and Selling Activity at Stryker

This chart shows M Kathryn Fink's buying and selling at Stryker by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Stryker Company Overview

Stryker logo
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Read More

Today's Range

Now: $384.88
Low: $381.58
High: $390.66

50 Day Range

MA: $366.20
Low: $345.14
High: $390.08

2 Week Range

Now: $384.88
Low: $285.79
High: $398.20

Volume

1,069,680 shs

Average Volume

1,269,104 shs

Market Capitalization

$146.72 billion

P/E Ratio

41.25

Dividend Yield

0.82%

Beta

0.91